Predicting Sites of Tumour Progression in the Invasive Margin of Glioblastomas (PRaM-GBM Study)

Launched by CCTU- CANCER THEME · Sep 22, 2017

Keywords

ClinConnect Summary

This is a multicentre, prospective longitudinal observational cohort study in patients with high grade glioma, who have surgery planned to remove \>90% of the tumour, and subsequent radical radiotherapy with concomitant tomozolomide. The purpose of this study is to establish a model using DTI that can accurately predict the site of where glioblastomas will progress after treatment. This study aims to validate the use of DTI as a biomarker across multiple centres to develop analysis methods that could be used in the future to personalise radiotherapy treatment volumes, and potentially surgic...

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Have given written informed consent to participate
• • Assessed by a neuroscience MDT to have a high grade glioma on imaging, OR if in the opinion of the CI, with guidance from the local PI that all relevant and appropriate members of a multidisciplinary team agree a high grade glioma diagnosis;
• • Considered suitable for radical radiotherapy (60 Gy) with concomitant chemotherapy (Stupp Regime);
• • WHO PS 0 or 1 (see Appendix 3);
• • Age ≥16;
• • Patient suitable for tumour resection where the treating neurosurgeon feels that \>90% of the enhancing tumour will be resected;
• Exclusion Criteria:
• • Patients who are participating in trials involving investigational treatments
• * Patients who are unsuitable for a contrast-enhanced MRI will be excluded. Such clinical problems include, but are not limited to:
• • MR unsafe metallic implants;
• • Claustrophobia;
• • Allergy to gadolinium contrast agent;
• • History of severe renal impairment.
• • Patients unable to provide written informed consent
• • PET sub-study only: Pregnant women